184 related articles for article (PubMed ID: 27404380)
21. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
22. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report.
Shigehiro M; Kita M; Takeuchi S; Ashihara Y; Arai M; Okamura H
Jpn J Clin Oncol; 2016 Mar; 46(3):254-9. PubMed ID: 26685323
[TBL] [Abstract][Full Text] [Related]
23. Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report.
Signorelli M; Bogani G; Ditto A; Martinelli F; Chiappa V; Lopez C; Scaffa C; Lorusso D; Raspagliesi F
Minerva Ginecol; 2016 Oct; 68(5):536-43. PubMed ID: 26844708
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer.
Disis ML
JAMA Oncol; 2015 Jun; 1(3):313. PubMed ID: 26181176
[No Abstract] [Full Text] [Related]
25. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
26. Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view.
De Felice F; Marchetti C
Oncotarget; 2015 Nov; 6(37):39391-2. PubMed ID: 26588056
[No Abstract] [Full Text] [Related]
27. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
[TBL] [Abstract][Full Text] [Related]
28. Salpingectomy as a means to reduce ovarian cancer risk.
Daly MB; Dresher CW; Yates MS; Jeter JM; Karlan BY; Alberts DS; Lu KH
Cancer Prev Res (Phila); 2015 May; 8(5):342-8. PubMed ID: 25586903
[TBL] [Abstract][Full Text] [Related]
29. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
30. Risk-reducing salpingectomy: Let us be opportunistic.
Long Roche KC; Abu-Rustum NR; Nourmoussavi M; Zivanovic O
Cancer; 2017 May; 123(10):1714-1720. PubMed ID: 28334425
[TBL] [Abstract][Full Text] [Related]
31. Role of salpingectomy at the time of urogynecologic surgery.
Bradley MS; Visco AG
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):385-9. PubMed ID: 26308195
[TBL] [Abstract][Full Text] [Related]
32. Salpingectomy and Ovarian Cancer Prevention.
Harris AL
Nurs Womens Health; 2015 Dec-2016 Jan; 19(6):543-9. PubMed ID: 26682662
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
34. A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
Yerushalmi R; Rizel S; Zoref D; Sharon E; Eitan R; Sabah G; Grubstein A; Rafson Y; Cohen M; Magen A; Birenboim I; Margel D; Ozlavo R; Sulkes A; Brenner B; Perry S
Isr Med Assoc J; 2016 Sep; 18(9):549-552. PubMed ID: 28471604
[TBL] [Abstract][Full Text] [Related]
35. Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK.
Chandrasekaran D; Menon U; Evans G; Crawford R; Saridogan E; Jacobs C; Tischkowitz M; Brockbank E; Kalsi J; Jurkovic D; Manchanda R
Fam Cancer; 2015 Dec; 14(4):521-30. PubMed ID: 26178205
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
37. Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.
Pölcher M; Hauptmann S; Fotopoulou C; Schmalfeldt B; Meinhold-Heerlein I; Mustea A; Runnebaum I; Sehouli J
Arch Gynecol Obstet; 2015 Jul; 292(1):231-4. PubMed ID: 25914073
[TBL] [Abstract][Full Text] [Related]
38. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study.
Madsen C; Baandrup L; Dehlendorff C; Kjaer SK
Acta Obstet Gynecol Scand; 2015 Jan; 94(1):86-94. PubMed ID: 25256594
[TBL] [Abstract][Full Text] [Related]
39. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
40. Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives.
Arts-de Jong M; Harmsen MG; Hoogerbrugge N; Massuger LF; Hermens RP; de Hullu JA
Gynecol Oncol; 2015 Feb; 136(2):305-10. PubMed ID: 25560807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
